Why Amylyx Pharmaceuticals, Inc.’s (AMLX) Stock Is Down 5.99%
As of Monday, November 16, Amylyx Pharmaceuticals, Inc.’s AMLX share price has dipped by 5.99%, which has investors questioning if this is right time to buy.Michael Rose
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Michael Rose
Jenna Brashear
Cynthia McLaughlin
Jenna Brashear
Tudor Pop
| Share Statistics | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $3,574.0 | $433.9 | 63% |
|
| Shares Out (Mil) | 118.9 | 46.5 | 65% |
|
| Institutional Ownership | 93.9% | 82.2% | 63% |
|
| Float (Mil) | 112.8 | 47.7 | 63% |
|
| Beta | -0.08 | 0.74 | 4% |
|
| Avg Daily Volume (000s) | 1,625 | 345 | 76% |
|
| Price Change (52-week) |
123.8% | 52.0% | 97% |
|
| Growth | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.4% | na |
|
| Net Income (5yr) | (27.9%) | (1.6%) | 15% |
|
| EPS (5yr) | 26.1% | 15.1% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (0.9%) | (15.1%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 8 | |
| Current EPS | ($0.369) | ($1.507) | ($1.129) | |
| Month Ago EPS | ($0.364) | ($1.484) | ($1.090) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 0 | 1 | 0 | |
| Three Months Ago EPS | ($0.359) | ($1.481) | ($1.138) | |
| Year/Year Chg | (3.4%) | (1.6%) | (55.2%) | |
| Financials | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $289 | na |
|
| Net Income (TTM) (Mil) | ($163) | ($11) | 8% |
|
| EPS (TTM) | ($1.448) | ($0.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($130) | ($7) | 5% |
|
| Net Cash Flow (TTM) (Mil) | $15 | $1 | 61% |
|
| Long-Term Debt (Q1) (Mil) | $4 | $6 | 23% |
|
| Enterprise Value (Q1) (Mil) | $3,029 | $331 | 55% |
|
| Valuation | AMLX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.74 | 2.05 | 80% |
|
| P/E | na | 24.3 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | AMLX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.5% | na |
|
| Net Margin | na | 3.9% | na |
|
| ROA | (28.4%) | (23.3%) | 17% |
|
| ROE | (30.1%) | (21.8%) | 20% |
|
| Liabilities to Assets | 4.2% | 31.2% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
Amylyx Pharmaceuticals, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors